Our results indicated that, even though the sensitivity of anti‐CRT Ab for identifying cancer was not superior to that of anti‐TIF‐1γ Ab, the detection of anti‐CRT Ab in clinical practice may be valuable in monitoring cancer recurrence in IIM patients with a history of solid tumors. The gene discussed is TRIM33; the disease is cancer.